SPOTLIGHT -
Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.
Implementation of Early End Points Could Represent New Standard for Breast Cancer Clinical Trials
FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer
Ribociclib Plus Endocrine Therapy Meets iDFS End Point in HR+ Early Breast Cancer
Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration
Results of NRG-BR002 Trial Point to Need for Additional Research of Local Therapy for Oligometastatic Breast Cancer
Newly Defined Breast Cancer Targets Expand TNBC Treatment Options
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC